Retinoids in lung cancer chemoprevention and treatment

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Toma, S ^a,b   Raffo, P ^a   Isnardi, L ^a   Palumbo, R ^a  

^a Advanced Biotechonology Center   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemoprevention; Lung cancer; Retinoids; Therapy

Indexed keywords

ALPHA INTERFERON; BETA CAROTENE; CISPLATIN; ETOPOSIDE; ETRETINATE; ISOTRETINOIN; PLACEBO; RETINOIC ACID; RETINOID; RETINOL; RETINOL PALMITATE;

CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0032736668     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S95     Document Type: Conference Paper

References (53)

1. Parker SL, Toug T, Bolden S. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992; 3: 513-26.
3. Lippman SM, Benner SE, Hong WK. retinoid chemoprevention in upper aerodigeslive tract and lung carcinogenesis. Cancer Res 1994; 54: 2025-8.
4. Fontham ETH. Protective dietary factors and lung cancer. Int J Epidemiol 1990; 19: 32-42.
5. Albanes D, Heinonen OP, Taylor PR et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study: Effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560-70.
6. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
7. Hong WK, Endicott J, Itri I et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-5.
8. Hong WK, Lippman SM, Itri I et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-800.
9. Warrel RP Jr, Frankel SR, Miller WH Jr. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93.
10. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1990; 10: 839-64.
11. Eisenhauer EA, Lippman SM, Kavanagh JJ et al. Combination 13-cis-retinoic acid and interferon-α-2a in the therapy of solid tumors. Leukemia 1994; 8 (10): 1622-5.
12. Chopra DP. Squamous metaplasia in organ cultures of vitamin A-deficiency hamster trachea: Cytokinetics and ultrastructural alteration. J Natl Cancer Inst 1982; 69: 895-901.
13. Saffiotti U, Montesano R, Sellakumar AR, Borg SA. Experimental cancer of the lung: Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous tumors. Cancer 1967; 20: 857-64.
14. de Thè H, Vivanco-Ruiz MM, Tiollais P et al. Identification of a retinoic acid response element in the retinoic acid receptor-β gene. Nature 1990; 343: 177-80.
15. Houle B, Leduc F, Bradley WE. Implication of RAR-β in epidermoid (squamous) lung cancer. Genes Chromosomes Cancer 1991; 3: 358-66.
16. Zhang X-K, Liu Y, Lee M-O, Pfahl M. A specific defect in the retinoic acid response associated with human lung cancer cell lines. Cancer Res 1994; 54: 5663-9.
17. Nervi C, Vollberg TM, George MD et al. Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells. Exp Cell Res 1991; 195: 163-70.
18. Li Y, Dawson MI, Agadir A et al. Regulation of RAR-β expression by RAR-and RXR-selective retinoids in human lung cancer cell lines: Effect on growth inhibition and apoptosis induction. Int J Cancer 1998; 75: 88-95.
19. Houle B, Rochette-Egly C, Bradley EC. Tumor-suppressive effect of the retinoic acid receptor-β in human epidermoid lung cancer cells. Proc Natl Acad Sci USA 1993; 90: 985-9.
20. Berard J, Laboune F, Mukuna M et al. Lung tumors in mice expressing an antisense RAR-β2 transgene. FASEB J 1996; 10: 1091-7.
21. Zhang X-K, Liu Y, Lee M-O. Retinoid receptors in human lung cancer and breast cancer. Mutation Res 1996; 350: 267-77.
22. Lotan R. Role of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. Environ Health Perspect 1997; 105 (4): 985-8.
23. Lotan R. Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metast Res 1997; 16: 349-56.
24. Xu XC, Sozzi G, Lee JS et al. Suppression of retinoic acid receptor-β in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 1997; 89 (9): 624-9.
25. Sun SY, Yue P, Shroot B et al. Induction of apoptosis in human non-small-cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol 1997; 173 (2): 279-84.
26. Kalemkerian GP, Slusher R, Ramalingam S et al. Growth inhibition and induction of apoptosis by fenretinide in small-cell-lung cancer cell lines. J Natl Cancer Inst 1995; 87 (22): 1674-80.
27. Toma S, Isnardi L, Raffo P et al. RAR-β antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast cancer cell lines. Int J Cancer 1998; 78: 86-94.
28. Slaughter DP, South HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
29. Gouveia J, Mathe G, Hercend T et al. Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1982; i: 710-2.
30. Misset JL, Mathe G, Santelli G et al. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Acta Vitaminol Enzymol 1985; 7: 21-6.
31. Arnold AM, Browman GP, Levine MN et al. The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomized trial. Br J Cancer 1992; 65: 737-43.
32. Lee JS, Lippman SM, Benner SE et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12: 937-45.
33. Saccomanno G, Moran PG, Schmidt RD et al. Effects of 13-cis-retinoids on premalignant and malignant cells of lung origin. Acta Cytol 1982; 26: 78-85.
34. De Klerk NH, Musk W, Ambrosini GL et al. Vitamin A and cancer prevention II: Comparison of the effects of retinol and β-carotene. Int J Cancer 1998; 75: 362-7.
35. Pastorino U, Infante M, Maioli M et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11: 1216-22.
36. Karp DD. Lung cancer chemoprevention and management of carcinoma in situ. Semin Oncol 1997; 24 (4): 402-10.
37. Micksche M, Cerny C, Kikron O et al. Stimulation of immune response in lung cancer patients by vitamin A therapy. Oncology 1997; 34: 234-8.
38. Uphouse W, Oishi N, Berenberg J et al. Treatment of advanced non-small-cell lung cancer with 13-cis-retinoic acid. Proc Am Soc Clin Oncol 1987; 6: 712.
39. Goodman GE. Phase II trial of retinol in patients with advanced cancer. Cancer Treat Rep 1986; 70 (8): 1023-4.
40. Grunberg SM, Itri LM. Phase II study of isotretinoin in the treatment of advanced non-small-cell lung cancer. Cancer Treat Rep 1987; 71 (11): 1097-8.
41. Rinaldi AD, Lippman SM, Burris HA III et al. Phase II study of 13-cis-retinoic acid and interferon-α-2a in patients with advanced squamous cell lung cancer. Anti-Cancer Drugs 1993; 4: 33-6.
42. Roth AD, Abele R, Alberto P. 13-cis-retinoic acid plus interferon-α: A phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 1994; 51: 84-6.
43. Toma S, Palumbo R, Vincenti M et al. Efficacy of recombinant α-interferon-2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol 1994; 5: 463-5.
44. Arnold A, Ayoub J, Douglas L et al. Phase II trial of 13-cis-retinoic acid plus interferon-α in non-small-cell lung cancer. J Natl Cancer Inst 1994; 86(4): 306-9.
45. Hoffmann W, Schiebe M, Hirnle P et al. 13-cis-retinoic acid and interferon-α +/-irradiation in the treatment of squamous cell carcinomas. Int J Cancer 1997; 70: 475-7.
46. Hoffmann W, Bamberg M, Rodemann HP. Antiproliferative effects of ionizing radiation, all-trans-retinoic and interferon-α on cultured human squamous cell carcinomas. Radiat Oncol Invest 1994; 2: 12-9.
47. Treat J, Grenberg R, Bratschi J et al. First hints in non-small-cell lung cancer (NSCLC). Leukemia 1994; 8: 55-8.
48. Athanasiadis I, Kies M, Miller M et al. Phase II study of all-trans-retinoic acid and α-interferon in patients with advanced non-small-cell lung cancer. Clin Cancer Res 1995; 1: 973-5.
49. Thiruvengadam R, Atiba JO, Azawi SH. A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Invest N Drugs 1996; 14: 395-401.
50. Adamson PC, Bailey J, Pluda J et al. Pharmacokinetic of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995; 13: 1238-41.
51. Bailey J, Pluda JM, Foli A et al. Phase I-II study of intermittent all-trans-retinoic acid alone and in combination with interferon alfa-2a in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995; 13(8): 1966-74.
52. Regazzi MB, Iacona I, Gervasutti C et al. Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet 1997; 32 (5): 382-402.
53. Toma S, Palumbo R, Rosso R, Results. Toxicity and compliance in chemoprevention trials of head and neck cancer. Eur J Cancer Prev 1993; 3: 63-8.